+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics

  • Book

  • April 2024
  • Elsevier Science and Technology
  • ID: 5894866

"Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics� provides a comprehensive overview and update of the mass-action law-based unified dose-effect biodynamics, pharmacodynamics, bioinformatics, and the combination index theorem for synergy definition (MAL-BD/PD/BI/CI). Contents advocate the fundamental MAL-PD/BI/CI/BI principle for biomedical R&D, clinical trials protocol design computerized data analysis, illustrates the MAL-dynamics theory with sample analysis, and includes data entry and automated computer report print-outs. In 11 sections "Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics� leads the reader from an introduction and overview, to trial protocols and MAL-PD/CI approach for biomedical R&D in vitro and in animals. It describes the current Landscape of International FDA Drug Evaluation, Clinical Pharmacology, and Clinical Trials Guidance. This is a valuable resource for biomedical researchers, healthcare professionals, and students seeking to harness the power of data informatics in precision medicine.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. A new alternative concept for cost-effective R&D: The MALdynamics/algorithms/digital informatics
2. General dynamics principle for experimental design of all dose-effect analysis and computer simulation
3. MAL-PD/CI approach for biomedical R&D in vitro and in animals
4. Implementation for MAL-PD Econo-Green R&D
5. Digital R&D approach to international FDA drug evaluation, clinical pharmacology, and clinical trial guidance
6. The epothilone story: Experimental success and clinical failure
7. MAL-PD Advocacy: Public hearing, public comments and scientific recommendations
8. Consensus for international FDAs on definitions of “MAL-PD” and “Synergism”
9. Historical, philosophical, and mathematical analysis: Why the MAL-PD approach and the traditional approach are opposite yet complementary
10. Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method
11. Concluding remarks

Authors

Ting-Chao Chou PD Science LLC. Born in Taiwan, Ting-Chao (David) Chou received his Ph.D. in Pharmacology from Yale University and completed his Post-Doctoral Fellowship at Johns Hopkins University School of Medicine. He joined Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and became a Member and Professor of Pharmacology at Cornell University Graduate School of Medical Sciences in 1988. He retired from MSKCC in 2013 and founded PD Science LLC. Professor Chou was elected to the Membership of The Johns Hopkins Society of Scholars, induced by the President of JHU on April 8, 2019, among 16 national and international inductees. Dr. Chou's published 375 papers have garnered over forty thousand hundred citations with an h-index of 75 and i10-index of 290. He is the inventor/co-inventor of 40 U.S. patents. Currently, he advocates for MAL-based digital biomedical R&D for translational medicine bioinformatics (BI) to provide a complementary alternative basic framework to the traditional statistics-based R&D